|
Jul 11
|
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly
|
|
Jul 11
|
Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update
|
|
Jul 3
|
VALNEVA Declaration of shares and voting rights: June 30, 2025
|
|
Jun 26
|
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
|
|
Jun 25
|
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance
|
|
Jun 6
|
Valneva reports data from Phase II chikungunya vaccine trial in children
|
|
Jun 5
|
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
|
|
Jun 5
|
[Valneva SE] Declaration of shares and voting rights - May 2025
|
|
Jun 4
|
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
|
|
May 12
|
Valneva’s chikungunya vaccine use halted in older adults amid safety concerns
|
|
May 12
|
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
|
|
May 9
|
Eli Lilly extends Purdue alliance; EMA investigates Valneva shot
|
|
May 8
|
Valneva SE (INRLF) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...
|
|
May 7
|
VALNEVA Declaration of shares and voting rights: April 30, 2025
|
|
May 7
|
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
|
|
May 7
|
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
|
|
Apr 10
|
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study
|
|
Apr 9
|
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
|
|
Apr 8
|
Exploring Three High Growth Tech Stocks In Europe
|
|
Jan 3
|
VALNEVA Declaration of shares and voting rights: December 31, 2024
|